empagliflozin and linagliptin
Generic Name: empagliflozin and linagliptin (EM pa gli FLOE zin and LIN a GLIP tin)
Brand Name: Glyxambi
What is empagliflozin and linagliptin?
Empagliflozin and linagliptin are oral diabetes medicines that help control blood sugar levels. Empagliflozin works by helping the kidneys get rid of glucose from your bloodstream. Linagliptin works by regulating the levels of insulin your body produces after eating.
Empagliflozin and linagliptin is a combination medicine used together with diet and exercise to improve blood sugar control in adults with diabetes mellitus.
Empagliflozin and linagliptin is also used to lower the risk of death from heart attack, stroke, or heart failure in adults with type 2 diabetes who also have heart disease.
This medicine is not for treating type 1 diabetes.
Empagliflozin and linagliptin may also be used for purposes not listed in this medication guide.
What is the most important information I should know about empagliflozin and linagliptin?
You should not use this medicine if you have severe kidney disease (or if you are on dialysis), if you have ever had a severe allergic reaction to empagliflozin or linagliptin, or if you are in a state of diabetic ketoacidosis.
Call your doctor at once if you have signs of a serious side effect, such as severe pain in your upper stomach spreading to your back, vomiting, fast heart rate, dizziness, feeling very thirsty or hot, decreased urination, heavy sweating, or hot and dry skin.
What should I discuss with my healthcare provider before taking empagliflozin and linagliptin?
You should not use empagliflozin and linagliptin if you are allergic to it, or if you have:
severe kidney disease (or if you are on dialysis);
a history of severe allergic or skin reaction after taking linagliptin; or
if you are in a state of diabetic ketoacidosis (call your doctor for treatment with insulin).
To make sure empagliflozin and linagliptin is safe for you, tell your doctor if you have ever had:
a pancreas disorder;
low blood pressure;
high cholesterol or triglycerides (a type of fat in the blood);
a genital infection (penis or vagina);
if you are on a low salt diet; or
if you are 65 or older.
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It is not known whether empagliflozin and linagliptin passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.
How should I take empagliflozin and linagliptin?
Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Empagliflozin and linagliptin is usually taken in the morning. You may take this medicine with or without food.
Your blood sugar will need to be checked often, and you may also need to test the level of ketones your urine. Empagliflozin can cause life-threatening ketoacidosis (too much acid in the blood). Even if your blood sugar is normal, contact your doctor if a urine test shows that you have ketones in the urine.
Low blood sugar (hypoglycemia) can happen to everyone who has diabetes. Symptoms include headache, hunger, sweating, irritability, dizziness, nausea, fast heart rate, and feeling anxious or shaky. To quickly treat low blood sugar, always keep a fast-acting source of sugar with you such as fruit juice, hard candy, crackers, raisins, or non-diet soda.
Your doctor can prescribe a glucagon emergency injection kit to use in case you have severe hypoglycemia and cannot eat or drink. Be sure your family and close friends know how to give you this injection in an emergency.
Also watch for signs of high blood sugar (hyperglycemia) such as increased thirst or urination, blurred vision, headache, and tiredness.
Blood sugar levels can be affected by stress, illness, surgery, exercise, alcohol use, or skipping meals. Ask your doctor before changing your dose or medication schedule.
This medicine can cause unusual results with certain lab tests for glucose (sugar) in the urine. Tell any doctor who treats you that you are using empagliflozin and linagliptin.
Store at room temperature away from moisture and heat.
What happens if I miss a dose?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An empagliflozin and linagliptin overdose can cause life threatening hypoglycemia.
Symptoms of severe hypoglycemia include extreme weakness, confusion, tremors, sweating, fast heart rate, trouble speaking, nausea, vomiting, rapid breathing, fainting, and seizure (convulsions).
What should I avoid while taking empagliflozin and linagliptin?
Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.
Empagliflozin and linagliptin side effects
Get emergency medical help if you have signs of an allergic reaction: hives, itching, flaking or peeling skin; trouble swallowing, difficult breathing; swelling of your face, lips, tongue, or throat.
Stop taking this medicine and call your doctor at once if you have:
severe or ongoing pain in your joints;
serious skin reaction--itching, blisters, breakdown of the outer layer of skin;
ketoacidosis (too much acid in the blood)--nausea, vomiting, stomach pain, confusion, unusual drowsiness, or trouble breathing;
pancreatitis--severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;
dehydration symptoms--dizziness, weakness, or light-headed feeling (like you might pass out);
signs of a bladder infection--pain or burning when you urinate, urine that looks cloudy, pain in pelvis or back;
signs of a genital infection (penis or vagina)--pain, burning, itching, rash, redness, odor, or discharge; or
symptoms of heart failure--shortness of breath (even while lying down), swelling in your legs or feet, rapid weight gain.
Common side effects may include:
sore throat; or
runny nose, stuffy nose, sinus pain.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Empagliflozin and linagliptin dosing information
Usual Adult Dose for Diabetes Type 2:
Initial dose: Empagliflozin 10 mg-linagliptin 5 mg orally once a day in the morning
-May increase to empagliflozin 25 mg-linagliptin 5 mg orally once a day for patients tolerating the lower dose
Maximum dose: Empagliflozin 25 mg-linagliptin 5 mg per day
-Empagliflozin has been shown to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV; however, the effectiveness of this combination drug on reducing the risk of CV death in patients with type 2 diabetes mellitus and CV disease has not been established.
-When used in combination with insulin or insulin secretagogues, a lower dose of the insulin secretagogues or insulin may be necessary to reduce the risk of hypoglycemia.
Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.
What other drugs will affect empagliflozin and linagliptin?
Other drugs may increase or decrease the effects of empagliflozin and linagliptin on lowering your blood sugar. Tell your doctor about all your current medicines and any you start or stop using, especially:
other oral diabetes medicine;
rifampin (to treat tuberculosis); or
heart or blood pressure medication, including a diuretic or "water pill."
This list is not complete. Other drugs may interact with empagliflozin and linagliptin, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
More about empagliflozin/linagliptin
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 11 Reviews – Add your own review/rating
- Drug class: antidiabetic combinations
Other brands: Glyxambi
Related treatment guides
Where can I get more information?
- Your pharmacist can provide more information about empagliflozin and linagliptin.
- Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
- Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2012 Cerner Multum, Inc. Version: 1.07.
Date modified: November 15, 2017
Last reviewed: August 16, 2017